Gilead Sciences, Inc. (NASDAQ:GILD) Upgraded at ValuEngine

Gilead Sciences, Inc. (NASDAQ:GILD) was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a report released on Thursday, September 7th.

Several other equities analysts have also recently issued reports on GILD. BidaskClub cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $81.00 price target (up from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Leerink Swann reaffirmed a “hold” rating and issued a $74.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 25th. Cowen and Company reaffirmed an “outperform” rating and issued a $90.00 price target on shares of Gilead Sciences in a research note on Thursday, July 27th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a $86.00 price target (up from $79.00) on shares of Gilead Sciences in a research note on Sunday, August 20th. Eleven investment analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $83.79.

Shares of Gilead Sciences (NASDAQ:GILD) traded up 0.09% during mid-day trading on Thursday, reaching $82.36. 12,401,948 shares of the company’s stock were exchanged. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $86.27. The stock’s 50-day moving average is $77.16 and its 200-day moving average is $70.20. The stock has a market cap of $107.56 billion, a price-to-earnings ratio of 8.95 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same period in the previous year, the firm earned $3.08 earnings per share. The business’s revenue was down 8.2% compared to the same quarter last year. On average, equities analysts expect that Gilead Sciences will post $8.75 EPS for the current year.

WARNING: “Gilead Sciences, Inc. (NASDAQ:GILD) Upgraded at ValuEngine” was posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.truebluetribune.com/2017/09/17/gilead-sciences-inc-gild-raised-to-strong-buy-at-valuengine.html.

In related news, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the transaction, the chief financial officer now directly owns 43,352 shares in the company, valued at $3,684,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the transaction, the insider now owns 3,199,969 shares in the company, valued at $227,197,799. The disclosure for this sale can be found here. Insiders sold a total of 466,819 shares of company stock valued at $36,740,240 in the last ninety days. 1.30% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after purchasing an additional 1,937,031 shares during the period. Vanguard Group Inc. lifted its position in shares of Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after acquiring an additional 2,148,697 shares during the period. Bank of New York Mellon Corp raised its position in shares of Gilead Sciences by 1.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after purchasing an additional 310,607 shares during the last quarter. FMR LLC raised its position in shares of Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares during the last quarter. Finally, Parnassus Investments CA raised its position in shares of Gilead Sciences by 37.4% during the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after purchasing an additional 4,556,901 shares during the last quarter. 74.05% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply